Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Lisata Therapeutics (LSTA) Gross Profit (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Gross Profit readings, the most recent being -$119565.0 for Q1 2017.

  • For the quarter ending Q1 2017, Gross Profit fell 109.48% year-over-year to -$119565.0, compared with a TTM value of $2.8 million through Mar 2017, up 173.47%, and an annual FY2016 reading of $4.1 million, up 78.11% over the prior year.
  • Gross Profit hit -$119565.0 in Q1 2017 for Lisata Therapeutics, down from $931390.0 in the prior quarter.
  • The five-year high for Gross Profit was $1.3 million in Q1 2016, with the low at -$6.2 million in Q4 2015.
  • Median Gross Profit over the past 5 years was $124382.0 (2013), compared with a mean of -$890273.4.
  • The sharpest move saw Gross Profit crashed 3052.89% in 2014, then skyrocketed 1732.11% in 2016.
  • Year by year, Gross Profit stood at $734049.0 in 2013, then plummeted by 666.45% to -$4.2 million in 2014, then crashed by 48.51% to -$6.2 million in 2015, then soared by 115.08% to $931390.0 in 2016, then tumbled by 112.84% to -$119565.0 in 2017.
  • According to Business Quant data, Gross Profit over the past three periods came in at -$119565.0, $931390.0, and $706265.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.